Astellas Pharma Global Development, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

Phase 4

Completed

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions: Drug: Enzalutamide

First Posted Date: 2013-11-07

Last Posted Date: 2024-12-06

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 424

Registration Number: NCT01977651

Locations: 🇦🇺
Site AU61011, Sydney, New South Wales, Australia
🇺🇸
Site US10039, Syracuse, New York, United States
🇺🇸
Site US10008, Dallas, Texas, United States

and more 73 locations

A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor

Phase 2

Completed

Conditions: Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients

Interventions: Biological: ASP0113
Drug: Placebo

First Posted Date: 2013-11-01

Last Posted Date: 2024-10-24

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 150

Registration Number: NCT01974206

Locations: 🇺🇸
Site US10003, Los Angeles, California, United States
🇺🇸
Site US10001, Cleveland, Ohio, United States
🇺🇸
Site US10004, San Diego, California, United States

and more 50 locations

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

Phase 1

Completed

Conditions: Metastatic Urothelial Cancer

Interventions: Drug: AGS15E

First Posted Date: 2013-10-16

Last Posted Date: 2024-11-01

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 93

Registration Number: NCT01963052

Locations: 🇺🇸
Site US00006, Birmingham, Alabama, United States
🇺🇸
Site US00011, Pittsburgh, Pennsylvania, United States
🇺🇸
Site US00008, Seattle, Washington, United States

and more 8 locations

Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin

Phase 1

Completed

Conditions: Healthy Subjects
Pharmacokinetics of ASP015K

Interventions: Drug: ASP015K
Drug: Rosuvastatin

First Posted Date: 2013-10-10

Last Posted Date: 2013-10-10

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 24

Registration Number: NCT01959399

Locations: 🇺🇸
PAREXEL - Early Phase Unit, Glendale, California, United States

A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects

Phase 1

Completed

Conditions: Bioavailability of ASP015K
Healthy Subjects
Pharmacokinetics of ASP015K
Food Effect of ASP015K

Interventions: Drug: ASP015K

First Posted Date: 2013-08-28

Last Posted Date: 2013-09-16

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 36

Registration Number: NCT01929577

Locations: 🇺🇸
Parexel - Early Phase Clinical Unit, Baltimore, Maryland, United States

Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Regadenoson
Drug: Placebo

First Posted Date: 2013-08-08

Last Posted Date: 2013-08-30

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 36

Registration Number: NCT01918995

Locations: 🇺🇸
Parexel Early Phase Unit, Baltimore, Maryland, United States

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin

Phase 1

Completed

Conditions: Pharmacokinetics of Isavuconazole
Pharmacokinetics of Metformin
Healthy Subjects

Interventions: Drug: isavuconazole
Drug: metformin

First Posted Date: 2013-06-24

Last Posted Date: 2013-06-24

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 24

Registration Number: NCT01884558

Locations: 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate

Phase 1

Completed

Conditions: Pharmacokinetics of Isavuconazole
Pharmacokinetics of Methotrexate
Pharmacokinetics of 7-hydroxymethotrexate
Healthy Subjects

Interventions: Drug: isavuconazole
Drug: methotrexate

First Posted Date: 2013-06-24

Last Posted Date: 2013-06-24

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 24

Registration Number: NCT01884636

Locations: 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Phase 3

Completed

Conditions: Cytomegalovirus (CMV)-Positive Recipients
Allogeneic, Hematopoietic Cell Transplant (HCT)

Interventions: Biological: ASP0113
Drug: Placebo

First Posted Date: 2013-06-14

Last Posted Date: 2024-10-24

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 514

Registration Number: NCT01877655

Locations: 🇺🇸
Site US10045, Houston, Texas, United States
🇺🇸
Site US10039, Seattle, Washington, United States
🇯🇵
Site JP81010, Bunkyo-ku, Tokyo, Japan

and more 80 locations

Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects

Phase 1

Completed

Conditions: Pharmacokinetics of 14C-labeled Isavuconazole
Healthy Subjects

Interventions: Drug: 14C-labeled prodrug isavuconazonium sulfate

First Posted Date: 2013-03-19

Last Posted Date: 2013-03-19

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 8

Registration Number: NCT01813461

Locations: 🇺🇸
Covance, Madison, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy